A fresh perspective from immunologists and vaccine researchers: Active vaccination strategies to prevent and reverse Alzheimer's disease

Alzheimer's and Dementia

Volumn 11, Issue 10, 2015, Pages 1246-1259

  Agadjanyan, Michael G ^a,b   Petrovsky, Nikolai ^c,d   Ghochikyan, Anahit ^a  

^a INSTITUTE FOR MOLECULAR MEDICINE   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c VAXINE PTY LTD   (Australia)

^d FLINDERS UNIVERSITY   (Australia)

Author keywords

Alzheimer's disease; Antibody titers; B cell epitope; Clinical trials; Tau protein; Th cell epitope; Vaccine; amyloid

Indexed keywords

ALZHEIMER DISEASE VACCINE; AMYLOID BETA PROTEIN; EPITOPE; TAU PROTEIN;

ALZHEIMER DISEASE; ARTICLE; CELLULAR IMMUNITY; DRUG EFFICACY; HUMAN; HUMORAL IMMUNITY; IMMUNOGENICITY; IMMUNOLOGIST; NONHUMAN; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; STANDARDIZATION; VACCINATION; ANIMAL; ANTIBODY PRODUCTION; CLINICAL TRIAL (TOPIC); IMMUNOLOGY;

ALZHEIMER DISEASE; ALZHEIMER VACCINES; ANIMALS; ANTIBODY FORMATION; CLINICAL TRIALS AS TOPIC; HUMANS; TAU PROTEINS; VACCINATION;

EID: 84945465570     PISSN: 15525260     EISSN: 15525279     Source Type: Journal    
DOI: 10.1016/j.jalz.2015.06.1884     Document Type: Article

References (166)

1. S. Riedel Edward Jenner and the history of smallpox and vaccination Proc (Bayl Univ Med Cent) 18 2005 21 25
2. A.J. Morgan, and S. Parker Translational mini-review series on vaccines: The Edward Jenner Museum and the history of vaccination Clin Exp Immunol 147 2007 389 394
3. N. Petrovsky, and J.C. Aguilar Vaccine adjuvants: Current state and future trends Immunol Cell Biol 82 2004 488 496
4. N. Petrovsky Unconventional vaccines: Progress and challenges J Vaccines Vaccin 4 2013 186
5. U.S. Food and Drug Administration Vaccines, blood & biologics. Vaccines licensed for immunization and distribution in the US with supporting documents Available at: http://www.fda.gov/BiologicsBloodVaccines/Vaccines/ApprovedProducts/ucm093830.htm Accessed July 30, 2015
6. M. Vazquez, P.S. LaRussa, A.A. Gershon, S.P. Steinberg, K. Freudigman, and E.D. Shapiro The effectiveness of the varicella vaccine in clinical practice N Engl J Med 344 2001 955 960
7. M.N. Oxman, M.J. Levin, G.R. Johnson, K.E. Schmader, S.E. Straus, L.D. Gelb, and et al. A vaccine to prevent herpes zoster and postherpetic neuralgia in older adults N Engl J Med 352 2005 2271 2284
8. C.M. Hales, R. Harpaz, I. Ortega-Sanchez, and S.R. Bialek Update on recommendations for use of herpes zoster vaccine MMWR Morb Mortal Wkly Rep 63 2014 729 731
9. O. Papaloukas, G. Giannouli, and V. Papaevangelou Successes and challenges in varicella vaccine Ther Adv Vaccines 2 2014 39 55
10. P.W. Kantoff, C.S. Higano, N.D. Shore, E.R. Berger, E.J. Small, D.F. Penson, and et al. Sipuleucel-T immunotherapy for castration-resistant prostate cancer N Engl J Med 363 2010 411 422
11. J.M. Reichert Therapeutic monoclonal antibodies approved or in review in the European Union or United States Available at: http://www.antibodysociety.org/news/approved-mabs.php Accessed July 30, 2015
12. J.M. Reichert Antibodies to watch in 2015 MAbs 7 2015 1 8
13. J. Hardy, and D.J. Selkoe The amyloid hypothesis of Alzheimer's disease: Progress and problems on the road to therapeutics Science 297 2002 353 356
14. J.A. Hardy, and G.A. Higgins Alzheimer's disease: the amyloid cascade hypothesis Science 256 1992 184 185
15. R. Kayed, and C.A. Lasagna-Reeves Molecular mechanisms of amyloid oligomers toxicity J Alzheimers Dis 33 Suppl 1 2013 S67 S78
16. W. Cerpa, M.C. Dinamarca, and N.C. Inestrosa Structure-function implications in Alzheimer's disease: Effect of Abeta oligomers at central synapses Curr Alzheimer Res 5 2008 233 243
17. R.E. Tanzi The genetics of Alzheimer disease Cold Spring Harb Perspect Med 2 10 2012
18. A. Granic, J. Padmanabhan, M. Norden, and H. Potter Alzheimer Abeta peptide induces chromosome mis-segregation and aneuploidy, including trisomy 21: Requirement for tau and APP Mol Biol Cell 21 2010 511 520
19. H. Potter Review and hypothesis: Alzheimer disease and Down syndrome - chromosome 21 nondisjunction may underlie both disorders Am J Hum Genet 48 1991 1192 1200
20. I. Klyubin, D.M. Walsh, C.A. Lemere, W.K. Cullen, G.M. Shankar, V. Betts, and et al. Amyloid beta protein immunotherapy neutralizes Abeta oligomers that disrupt synaptic plasticity in vivo Nat Med 11 2005 556 561
21. S. Salomone, F. Caraci, G.M. Leggio, J. Fedotova, and F. Drago New pharmacological strategies for treatment of Alzheimer's disease: Focus on disease modifying drugs Br J Clin Pharmacol 73 2012 504 517
22. B.S. Gadad, G.B. Britton, and K.S. Rao Targeting oligomers in neurodegenerative disorders: Lessons from alpha-synuclein, tau, and amyloid-beta peptide J Alzheimers Dis 24 Suppl 2 2011 223 232
23. D. Schenk, R. Barbour, W. Dunn, G. Gordon, H. Grajeda, T. Guido, and et al. Immunization with amyloid-beta attenuates Alzheimer-disease-like pathology in the PDAPP mouse [see comments] Nature 400 1999 173 177
24. D. Schenk, M. Hagen, and P. Seubert Current progress in beta-amyloid immunotherapy Curr Opin Immunol 16 2004 599 606
25. D. Morgan, D.M. Diamond, P.E. Gottschall, K.E. Ugen, C. Dickey, J. Hardy, and et al. A beta peptide vaccination prevents memory loss in an animal model of Alzheimer's disease Nature 408 2000 982 985
26. C. Janus, M.A. Chishti, and D. Westaway Transgenic mouse models of Alzheimer's disease Biochim Biophys Acta 1502 2000 63 75
27. G. Chen, K.S. Chen, J. Knox, J. Inglis, A. Bernard, S.J. Martin, and et al. A learning deficit related to age and beta-amyloid plaques in a mouse model of Alzheimer's disease Nature 408 2000 975 979
28. F. Bard, C. Cannon, R. Barbour, R.L. Burke, D. Games, H. Grajeda, and et al. Peripherally administered antibodies against amyloid beta-peptide enter the central nervous system and reduce pathology in a mouse model of Alzheimer disease Nat Med 6 2000 916 919
29. R.B. DeMattos, K.R. Bales, D.J. Cummins, J.C. Dodart, S.M. Paul, and D.M. Holtzman Peripheral anti-Abeta antibody alters CNS and plasma Abeta clearance and decreases brain Abeta burden in a mouse model of Alzheimer's disease Proc Natl Acad Sci U S A 98 2001 8850 8855
30. J.C. Dodart, K.R. Bales, K.S. Gannon, S.J. Greene, R.B. DeMattos, C. Mathis, and et al. Immunization reverses memory deficits without reducing brain Abeta burden in Alzheimer's disease model Nat Neurosci 5 2002 452 457
31. D.M. Wilcock, A. Rojiani, A. Rosenthal, S. Subbarao, M.J. Freeman, M.N. Gordon, and et al. Passive immunotherapy against Abeta in aged APP-transgenic mice reverses cognitive deficits and depletes parenchymal amyloid deposits in spite of increased vascular amyloid and microhemorrhage J Neuroinflammation 1 2004 24
32. F. Bard, R. Barbour, C. Cannon, R. Carretto, M. Fox, D. Games, and et al. Epitope and isotype specificities of antibodies to beta-amyloid peptide for protection against Alzheimer's disease-like neuropathology Proc Natl Acad Sci U S A 100 2003 2023 2028
33. B.J. Bacskai, S.T. Kajdasz, R.H. Christie, C. Carter, D. Games, P. Seubert, and et al. Imaging of amyloid-beta deposits in brains of living mice permits direct observation of clearance of plaques with immunotherapy Nat Med 7 2001 369 372
34. D.M. Wilcock, S.K. Munireddy, A. Rosenthal, K.E. Ugen, M.N. Gordon, and D. Morgan Microglial activation facilitates Abeta plaque removal following intracranial anti-Abeta antibody administration Neurobiol Dis 15 2004 11 20
35. B. Solomon, R. Koppel, D. Frankel, and E. Hanan-Aharon Disaggregation of Alzheimer beta-amyloid by site-directed mAb Proc Natl Acad Sci U S A 94 1997 4109 4112
36. D. Frenkel, M. Balass, and B. Solomon N-terminal EFRH sequence of Alzheimer's beta-amyloid peptide represents the epitope of its anti-aggregating antibodies J Neuroimmunol 88 1998 85 90
37. D. Frenkel, M. Balass, E. Katchalski-Katzir, and B. Solomon High affinity binding of monoclonal antibodies to the sequential epitope EFRH of beta-amyloid peptide is essential for modulation of fibrillar aggregation J Neuroimmunol 95 1999 136 142
38. B.J. Bacskai, S.T. Kajdasz, M.E. McLellan, D. Games, P. Seubert, D. Schenk, and et al. Non-Fc-mediated mechanisms are involved in clearance of amyloid-beta in vivo by immunotherapy J Neurosci 22 2002 7873 7878
39. R.B. DeMattos, K.R. Bales, D.J. Cummins, S.M. Paul, and D.M. Holtzman Brain to plasma amyloid-beta efflux: A measure of brain amyloid burden in a mouse model of Alzheimer's disease Science 295 2002 2264 2267
40. R.B. DeMattos, K.R. Bales, M. Parsadanian, M.A. O'Dell, E.M. Foss, S.M. Paul, and et al. Plaque-associated disruption of CSF and plasma amyloid-b (Ab) equilibrium in a mouse model of Alzheimer's disease J Neurochem 81 2002 229 236
41. Eli Lilly and Company Announcement Eli Lilly and Company announces top-line results on solanezumab phase 3 clinical trials in patients with Alzheimer's disease Available at: http://newsroom.lilly.com/releasedetail.cfm?releaseid=702211 Accessed July 30, 2015
42. K. Lobello, J.M. Ryan, E. Liu, G. Rippon, and R. Black Targeting beta amyloid: A clinical review of immunotherapeutic approaches in Alzheimer's disease Int J Alzheimers Dis 2012 2012 628070
43. L. Lannfelt, N.R. Relkin, and E.R. Siemers Amyloid-β-directed immunotherapy for Alzheimer's disease J Intern Med 275 2014 284 295
44. J. Delrieu, P.J. Ousset, C. Caillaud, and B. Vellas 'Clinical trials in Alzheimer's disease': Immunotherapy approaches J Neurochem 120 Suppl 1 2012 186 193
45. C.A. Lemere, and E. Masliah Can Alzheimer disease be prevented by amyloid-beta immunotherapy? Nat Rev Neurol 6 2010 108 119
46. A. Ghochikyan, and M.G. Agadjanyan CAD-106, a beta-amyloid-based immunotherapeutic for Alzheimer's disease 2012 Thompson Reuter New York
47. M.G. Agadjanyan, and D. Cribbs Active and passive Aβ-immunotherapy: Positive and negative outcomes from pre-clinical and clinical trials and future directions CNS Neurol Disord Drug Targets 8 1 & 2 2009
48. T. Wisniewski AD vaccines: Conclusions and future directions CNS Neurol Disord Drug Targets 8 2009 160 166
49. T. Wisniewski, and F. Goni Immunotherapy for Alzheimer's disease Biochem Pharmacol 88 2014 499 507
50. Alzforum Biogen antibody buoyed by phase 1 data and hungry investors 2015 Presented at the AD/PD Conference, March 25, 2015
51. Neurimmune. Aducanumab (BIIB037) reduced brain amyloid plaque levels and slowed cognitive decline in patients with prodromal or mild Alzheimer's disease in phase 1B study. Biogen Idec presents positive interim results from phase 1B study at 2015 AD/PD Conference 2015.
52. J.A. Nicoll, D. Wilkinson, C. Holmes, P. Steart, H. Markham, and R.O. Weller Neuropathology of human Alzheimer disease after immunization with amyloid-beta peptide: A case report Nat Med 9 2003 448 452
53. J.M. Orgogozo, S. Gilman, J.M. Dartigues, B. Laurent, M. Puel, L.C. Kirby, and et al. Subacute meningoencephalitis in a subset of patients with AD after Abeta42 immunization Neurology 61 2003 46 54
54. I. Ferrer, M.B. Rovira, M.L. Guerra, M.J. Rey, and F. Costa-Jussa Neuropathology and pathogenesis of encephalitis following amyloid-beta immunization in Alzheimer's disease Brain Pathol 14 2004 11 20
55. E. Masliah, L. Hansen, A. Adame, L. Crews, F. Bard, C. Lee, and et al. Abeta vaccination effects on plaque pathology in the absence of encephalitis in Alzheimer disease Neurology 64 2005 129 131
56. J.A. Nicoll, E. Barton, D. Boche, J.W. Neal, I. Ferrer, P. Thompson, and et al. Abeta species removal after abeta42 immunization J Neuropathol Exp Neurol 65 2006 1040 1048
57. R.L. Patton, W.M. Kalback, C.L. Esh, T.A. Kokjohn, G.D. Van Vickle, D.C. Luehrs, and et al. Amyloid-beta peptide remnants in AN-1792-immunized Alzheimer's disease patients: A biochemical analysis Am J Pathol 169 2006 1048 1063
58. S. Gilman, M. Koller, R.S. Black, L. Jenkins, S.G. Griffith, N.C. Fox, and et al. Clinical effects of Abeta immunization (AN1792) in patients with AD in an interrupted trial Neurology 64 2005 1553 1562
59. J. Grabenstein Vaccine excipient & media summary. ImmunoFacts: Vaccines and immunologic drugs - 2013 1st ed. 2012 Lippincott Williams & Wilkins Philadelphia
60. E.J. Mignot History of narcolepsy at Stanford University Immunol Res 58 2014 315 339
61. S.S. Ahmed, P.H. Schur, N.E. MacDonald, and L. Steinman Narcolepsy, 2009 A(H1N1) pandemic influenza, and pandemic influenza vaccinations: What is known and unknown about the neurological disorder, the role for autoimmunity, and vaccine adjuvants J Autoimmun 50 2014 1 11
62. T.F. Tsai, A. Crucitti, P. Nacci, U. Nicolay, G. Della Cioppa, J. Ferguson, and et al. Explorations of clinical trials and pharmacovigilance databases of MF59(R)-adjuvanted influenza vaccines for associated cases of narcolepsy Scand J Infect Dis 43 2011 702 706
63. N. Petrovsky Comparative safety of vaccine adjuvants: a summary of current evidence and future needs Drug Saf 2015 In Press
64. A.J. Bayer, R. Bullock, R.W. Jones, D. Wilkinson, K.R. Paterson, L. Jenkins, and et al. Evaluation of the safety and immunogenicity of synthetic Abeta42 (AN1792) in patients with AD Neurology 64 2005 94 101
65. N.C. Fox, R.S. Black, S. Gilman, M.N. Rossor, S.G. Griffith, L. Jenkins, and et al. Effects of Abeta immunization (AN1792) on MRI measures of cerebral volume in Alzheimer disease Neurology 64 2005 1563 1572
66. C. Hock, U. Konietzko, A. Papassotiropoulos, A. Wollmer, J. Streffer, R.C. Von Rotz, and et al. Generation of antibodies specific for beta-amyloid by vaccination of patients with Alzheimer disease Nat Med 8 2002 1270 1275
67. C. Holmes, D. Boche, D. Wilkinson, G. Yadegarfar, V. Hopkins, A. Bayer, and et al. Long-term effects of Abeta42 immunization in Alzheimer's disease: Follow-up of a randomised, placebo-controlled phase I trial Lancet 372 2008 216 223
68. C. Hock, U. Konietzko, J.R. Streffer, J. Tracy, A. Signorell, B. Muller-Tillmanns, and et al. Antibodies against beta-amyloid slow cognitive decline in Alzheimer's disease Neuron 38 2003 547 554
69. L. Van Parijs, and A.K. Abbas Homeostasis and self-tolerance in the immune system: Turning lymphocytes off Science 280 1998 243 248
70. D. Weiskopf, B. Weinberger, and B. Grubeck-Loebenstein The aging of the immune system Transpl Int 22 2009 1041 1050
71. R. Tarawneh, and D.M. Holtzman Critical issues for successful immunotherapy in Alzheimer's disease: Development of biomarkers and methods for early detection and intervention CNS Neurol Disord Drug Targets 8 2009 144 159
72. T.A. Kokjohn, and A.E. Roher Antibody responses, amyloid-beta peptide remnants and clinical effects of AN-1792 immunization in patients with AD in an interrupted trial CNS Neurol Disord Drug Targets 8 2009 88 97
73. C.Y. Wang, C.L. Finstad, A.M. Walfield, C. Sia, K.K. Sokoll, T.Y. Chang, and et al. Site-specific UBITh amyloid-beta vaccine for immunotherapy of Alzheimer's disease Vaccine 25 2007 3041 3052
74. B.G. Winblad, L. Minthon, A. Floesser, G. Imbert, T. Dumortier, Y. He, and et al. Results of the first-in-man study with the active Abeta immunotherapy CAD106 in Alzheimer's patients Alzheimers Dement 5 4, suppl. 2009 113 114
75. I. Petrushina, A. Ghochikyan, M. Mktrichyan, G. Mamikonyan, N. Movsesyan, H. Davtyan, and et al. Alzheimer's disease peptide epitope vaccine reduces insoluble but not soluble/oligomeric A{beta} species in amyloid precursor protein transgenic mice J Neurosci 27 2007 12721 12731
76. H. Davtyan, A. Ghochikyan, I. Petrushina, A. Hovakimyan, A. Davtyan, D.H. Cribbs, and et al. The MultiTEP platform-based Alzheimer's disease epitope vaccine activates a broad repertoire of T helper cells in nonhuman primates Alzheimers Dement 10 2014 271 283
77. J.M. Ryan, and M. Grundman Anti-amyloid-beta immunotherapy in Alzheimer's disease: ACC-001 clinical trials are ongoing J Alzheimers Dis 17 2009 243
78. K. Murphy, P. Travers, and M.J. Walport Janeway's Immunobiology 7th ed. 2008 Garland Science New York, US Abingdon, UK
79. C.A. Lemere Immunotherapy for Alzheimer's disease: Hoops and hurdles Mol Neurodegener 8 2013 36
80. F. Panza, V. Solfrizzi, B.P. Imbimbo, R. Tortelli, A. Santamato, and G. Logroscino Amyloid-based immunotherapy for Alzheimer's disease in the time of prevention trials: The way forward Expert Rev Clin Immunol 10 2014 405 419
81. B. Winblad, A. Graf, M.E. Riviere, N. Andreasen, and J.M. Ryan Active immunotherapy options for Alzheimer's disease Alzheimers Res Ther 6 2014 7
82. S.G. Reed, M.T. Orr, and C.B. Fox Key roles of adjuvants in modern vaccines Nat Med 19 2013 1597 1608
83. N. Petrovsky Freeing vaccine adjuvants from dangerous immunological dogma Expert Rev Vaccines 7 2008 7 10
84. A. Muhs, D.T. Hickman, M. Pihlgren, N. Chuard, V. Giriens, C. Meerschman, and et al. Liposomal vaccines with conformation-specific amyloid peptide antigens define immune response and efficacy in APP transgenic mice Proc Natl Acad Sci U S A 104 2007 9810 9815
85. C.F. Evans, H. Davtyan, I. Petrushina, A. Hovakimyan, A. Davtyan, D. Hannaman, and et al. Epitope-based DNA vaccine for Alzheimer's disease: Translational study in macaques Alzheimers Dement 10 2014 284 295
86. AlzForum In surprise, placebo, not Aβ vaccine, said to slow Alzheimer's Available at: http://www.alzforum.org/news/research-news/surprise-placebo-not-av-vaccine-said-slow-alzheimers Accessed July 30, 2015
87. AlzForum Vanutide cridificar Available at: http://www.alzforum.org/therapeutics/vanutide-cridificar Accessed July 30, 2015
88. V950-001 AM7. ClinicalTrials.gov Identifier: NCT00464334. 2014.
89. B. Winblad, N. Andreasen, L. Minthon, A. Floesser, G. Imbert, T. Dumortier, and et al. Safety, tolerability, and antibody response of active Abeta immunotherapy with CAD106 in patients with Alzheimer's disease: Randomised, double-blind, placebo-controlled, first-in-human study Lancet Neurol 11 2012 597 604
90. A. Schneeberger, M. Mandler, F. Mattner, and W. Schmidt AFFITOME(R) technology in neurodegenerative diseases: The doubling advantage Hum Vaccin 6 2010 948 952
91. H. Arai, H. Suzuki, and T. Yoshiyama Vanutide cridificar and the QS-21 adjuvant in Japanese subjects with mild to moderate Alzheimer's disease: Results from two phase 2 studies Curr Alzheimer Res 12 2015 242 254
92. S. Salloway, R. Sperling, N.C. Fox, K. Blennow, W. Klunk, M. Raskind, and et al. Two phase 3 trials of bapineuzumab in mild-to-moderate Alzheimer's disease N Engl J Med 370 2014 322 333
93. R.S. Doody, R.G. Thomas, M. Farlow, T. Iwatsubo, B. Vellas, S. Joffe, and et al. Phase 3 trials of solanezumab for mild-to-moderate Alzheimer's disease N Engl J Med 370 2014 311 321
94. H. Chertkow, H.H. Feldman, C. Jacova, and F. Massoud Definitions of dementia and predementia states in Alzheimer's disease and vascular cognitive impairment: Consensus from the Canadian conference on diagnosis of dementia Alzheimers Res Ther 5 Suppl 1 2013 S2
95. J.B. Langbaum, A.S. Fleisher, K. Chen, N. Ayutyanont, F. Lopera, Y.T. Quiroz, and et al. Ushering in the study and treatment of preclinical Alzheimer disease Nat Rev Neurol 9 2013 371 381
96. Hoffmann-La Roche. A Study of Gantenerumab in Patients With Prodromal Alzheimer's Disease. Identifier: NCT01224106.
97. DIAN study. Dominantly Inherited Alzheimer Network Trial: An Opportunity to Prevent Dementia. A Study of Potential Disease Modifying Treatments in Individuals at Risk for or With a Type of Early Onset Alzheimer's Disease Caused by a Genetic Mutation. Identifier: NCT01760005.
98. R.A. Sperling, D.M. Rentz, K.A. Johnson, J. Karlawish, M. Donohue, D.P. Salmon, and et al. The A4 study: Stopping AD before symptoms begin? Sci Transl Med 6 2014 228fs13
99. ADCS/A4. NCT02008357: Clinical Trial of Solanezumab for Older Individuals Who May be at Risk for Memory Loss (A4).
100. M. Medina, and J. Avila New perspectives on the role of tau in Alzheimer's disease. Implications for therapy Biochem Pharmacol 88 2014 540 547
101. C.A. Lemere, M. Maier, L. Jiang, Y. Peng, and T.J. Seabrook Amyloid-beta immunotherapy for the prevention and treatment of Alzheimer disease: Lessons from mice, monkeys, and humans Rejuvenation Res 9 2006 77 84
102. M. Maier, T.J. Seabrook, N.D. Lazo, L. Jiang, P. Das, C. Janus, and et al. Short amyloid-beta (Abeta) immunogens reduce cerebral Abeta load and learning deficits in an Alzheimer's disease mouse model in the absence of an Abeta-specific cellular immune response J Neurosci 26 2006 4717 4728
103. J. Nojima, A. Maeda, S. Aoki, S. Suo, D. Yanagihara, Y. Watanabe, and et al. Effect of rice-expressed amyloid beta in the Tg2576 Alzheimer's disease transgenic mouse model Vaccine 29 2011 6252 6258
104. F. Saade, S.A. Gorski, and N. Petrovsky Pushing the frontiers of T-cell vaccines: Accurate measurement of human T-cell responses Expert Rev Vaccines 11 2012 1459 1470
105. E. Derhovanessian, R. Solana, A. Larbi, and G. Pawelec Immunity, ageing and cancer Immun Ageing 5 2008 11
106. J.J. Goronzy, and C.M. Weyand Understanding immunosenescence to improve responses to vaccines Nat Immunol 14 2013 428 436
107. M. Pride, P. Seubert, M. Grundman, M. Hagen, J. Eldridge, and R.S. Black Progress in the active immunotherapeutic approach to Alzheimer's disease: Clinical investigations into AN1792-associated meningoencephalitis Neurodegener Dis 5 2008 194 196
108. M.R. Farlow, N. Andreasen, M.E. Riviere, I. Vostiar, A. Vitaliti, J. Sovago, and et al. Long-term treatment with active Abeta immunotherapy with CAD106 in mild Alzheimer's disease Alzheimers Res Ther 7 2015 23
109. B. Winblad, M. Farlow, K. Blennow, I. Vostiar, G. Imbert, A. Tomovic, and et al. Aβ-specific antibodies induced by active immunotherapy CAD106 engage Aβ in plasma in AD patients Alzheimers Dement 7 2011 S334
110. A. Ghochikyan, H. Davtyan, I. Petrushina, A. Hovakimyan, N. Movsesyan, A. Davtyan, and et al. Refinement of a DNA based Alzheimer's disease epitope vaccine in rabbits Hum Vaccin Immunother 9 2013 1002 1010
111. R. Kayed, E. Head, J.L. Thompson, T.M. McIntire, S.C. Milton, C.W. Cotman, and et al. Common structure of soluble amyloid oligomers implies common mechanism of pathogenesis Science 300 2003 486 489
112. J. McLaurin, R. Cecal, M.E. Kierstead, X. Tian, A.L. Phinney, M. Manea, and et al. Therapeutically effective antibodies against amyloid-beta peptide target amyloid-beta residues 4-10 and inhibit cytotoxicity and fibrillogenesis Nat Med 8 2002 1263 1269
113. G. Mamikonyan, M. Necula, M. Mkrtichyan, A. Ghochikyan, I. Petrushina, N. Movsesyan, and et al. Anti-Abeta 1-11 antibody binds to different beta-amyloid species, inhibits fibril formation, and disaggregates preformed fibrils, but not the most toxic oligomers J Biol Chem 282 2007 22376 22386
114. J. Legleiter, D.L. Czilli, B. Gitter, R.B. DeMattos, D.M. Holtzman, and T. Kowalewski Effect of different anti-Abeta antibodies on Abeta fibrillogenesis as assessed by atomic force microscopy J Mol Biol 335 2004 997 1006
115. M. Montanes, D. Casabona, L. Sarasa, P. Pesini, and M. Sarasa Prevention of amyloid-beta fibril formation using antibodies against the C-terminal region of amyloid-beta1-40 and amyloid-beta1-42 J Alzheimers Dis 34 2013 133 137
116. W. Berger Identification of subjects with a high risk of developing type I diabetes. Summary of a workshop, held on May 25th, 1984, in the Children's Hospital in Basel, Switzerland Bull Schweiz Akad Med Wiss 1984 81 85
117. C.F. Verge, D. Stenger, E. Bonifacio, P.G. Colman, C. Pilcher, P.J. Bingley, and et al. Combined use of autoantibodies (IA-2 autoantibody, GAD autoantibody, insulin autoantibody, cytoplasmic islet cell antibodies) in type 1 diabetes: Combinatorial Islet Autoantibody Workshop Diabetes 47 1998 1857 1866
118. P.J. Bingley, A.J. Williams, P.G. Colman, S.A. Gellert, G. Eisenbarth, L. Yu, and et al. Measurement of islet cell antibodies in the Type 1 Diabetes Genetics Consortium: Efforts to harmonize procedures among the laboratories Clin Trials 7 1 Suppl 2010 S56 S64
119. A.R. Mire-Sluis, R.G. Das, and A. Lernmark The development of a World Health Organisation international standard for islet cell antibodies: The aims and design of an international collaborative study Diabetes Metab Res Rev 15 1999 72 77
120. B.O. Roep, M.A. Atkinson, P.M. van Endert, P.A. Gottlieb, S.B. Wilson, and J.A. Sachs Autoreactive T cell responses in insulin-dependent (Type 1) diabetes mellitus. Report of the first international workshop for standardization of T cell assays J Autoimmun 13 1999 267 282
121. E. Kontsekova, N. Zilka, B. Kovacech, P. Novak, and M. Novak First-in-man tau vaccine targeting structural determinants essential for pathological tau-tau interaction reduces tau oligomerisation and neurofibrillary degeneration in an Alzheimer's disease model Alzheimers Res Ther 6 2014 44
122. Clinicaltrials.gov. NCT02031198: 18-months safety follow-up study of AADvac1, an active tau vaccine for Alzheimer's disease (FUNDAMANT). 2014. Available at: https://ct2/show/NCT02031198?term=Axon+Neuroscience&rank=1. Accessed July30, 2015.
123. AlzForum ACI-35 Available at: http://www.alzforum.org/therapeutics/aci-35 Accessed July 30, 2015
124. C. Ballatore, V.M. Lee, and J.Q. Trojanowski Tau-mediated neurodegeneration in Alzheimer's disease and related disorders Nat Rev Neurosci 8 2007 663 672
125. K. Iqbal, F. Liu, C.X. Gong, and I. Grundke-Iqbal Tau in Alzheimer disease and related tauopathies Curr Alzheimer Res 7 2010 656 664
126. C.A. Hawkes, R.O. Carare, and R.O. Weller Amyloid and tau in the brain in sporadic Alzheimer's disease: Defining the chicken and the egg Acta Neuropathol 127 2014 617 618
127. D.M. Mann, and J. Hardy Amyloid or tau: The chicken or the egg? Acta Neuropathol 126 2013 609 613
128. H. Braak, and K. Del Tredici Reply: The early pathological process in sporadic Alzheimer's disease Acta Neuropathol 126 2013 615 618
129. H. Braak, and E. Braak Neuropathological stageing of Alzheimer-related changes Acta Neuropathol (Berl) 82 1991 239 259
130. I. Alafuzoff, K. Iqbal, H. Friden, R. Adolfsson, and B. Winblad Histopathological criteria for progressive dementia disorders: Clinical-pathological correlation and classification by multivariate data analysis Acta Neuropathol 74 1987 209 225
131. B.E. Tomlinson, G. Blessed, and M. Roth Observations on the brains of demented old people J Neurol Sci 11 1970 205 242
132. C.R. Jack Jr., D.S. Knopman, W.J. Jagust, R.C. Petersen, M.W. Weiner, P.S. Aisen, and et al. Tracking pathophysiological processes in Alzheimer's disease: An updated hypothetical model of dynamic biomarkers Lancet Neurol 12 2013 207 216
133. R.J. Bateman, C. Xiong, T.L. Benzinger, A.M. Fagan, A. Goate, N.C. Fox, and et al. Clinical and biomarker changes in dominantly inherited Alzheimer's disease N Engl J Med 367 2012 795 804
134. J.E. Gerson, and R. Kayed Formation and propagation of tau oligomeric seeds Front Neurol 4 2013 93
135. F. Clavaguera, I. Lavenir, B. Falcon, S. Frank, M. Goedert, and M. Tolnay "Prion-like" templated misfolding in tauopathies Brain Pathol 23 2013 342 349
136. K. Yanamandra, N. Kfoury, H. Jiang, T.E. Mahan, S. Ma, S.E. Maloney, and et al. Anti-tau antibodies that block tau aggregate seeding in vitro markedly decrease pathology and improve cognition in vivo Neuron 80 2013 402 414
137. B. Frost, and M.I. Diamond Prion-like mechanisms in neurodegenerative diseases Nat Rev Neurosci 11 2010 155 159
138. J.L. Guo, and V.M. Lee Seeding of normal tau by pathological tau conformers drives pathogenesis of Alzheimer-like tangles J Biol Chem 286 2011 15317 15331
139. L. Liu, V. Drouet, J.W. Wu, M.P. Witter, S.A. Small, C. Clelland, and et al. Trans-synaptic spread of tau pathology in vivo PLoS One 7 2012 e31302
140. S. Dujardin, S. Begard, R. Caillierez, C. Lachaud, L. Delattre, S. Carrier, and et al. Ectosomes: A new mechanism for non-exosomal secretion of tau protein PLoS One 9 2014 e100760
141. Y. Yoshiyama, V.M. Lee, and J.Q. Trojanowski Therapeutic strategies for tau mediated neurodegeneration J Neurol Neurosurg Psychiatr 84 2013 784 795
142. J. Gu, and E.M. Sigurdsson Immunotherapy for tauopathies J Mol Neurosci 45 2011 690 695
143. A.A. Asuni, A. Boutajangout, D. Quartermain, and E.M. Sigurdsson Immunotherapy targeting pathological tau conformers in a tangle mouse model reduces brain pathology with associated functional improvements J Neurosci 27 2007 9115 9129
144. A. Boutajangout, D. Quartermain, and E.M. Sigurdsson Immunotherapy targeting pathological tau prevents cognitive decline in a new tangle mouse model J Neurosci 30 2010 16559 16566
145. M. Boimel, N. Grigoriadis, A. Lourbopoulos, E. Haber, O. Abramsky, and H. Rosenmann Efficacy and safety of immunization with phosphorylated tau against neurofibrillary tangles in mice Exp Neurol 224 2010 472 485
146. H. Rosenmann, N. Grigoriadis, D. Karussis, M. Boimel, O. Touloumi, H. Ovadia, and et al. Tauopathy-like abnormalities and neurologic deficits in mice immunized with neuronal tau protein Arch Neurol 63 2006 1459 1467
147. M. Bi, A. Ittner, Y.D. Ke, J. Gotz, and L.M. Ittner Tau-targeted immunization impedes progression of neurofibrillary histopathology in aged P301L tau transgenic mice PLoS One 6 2011 e26860
148. K. Schindowski, A. Bretteville, K. Leroy, S. Begard, J.P. Brion, M. Hamdane, and et al. Alzheimer's disease-like tau neuropathology leads to memory deficits and loss of functional synapses in a novel mutated tau transgenic mouse without any motor deficits Am J Pathol 169 2006 599 616
149. K. Leroy, A. Bretteville, K. Schindowski, E. Gilissen, M. Authelet, R. De Decker, and et al. Early axonopathy preceding neurofibrillary tangles in mutant tau transgenic mice Am J Pathol 171 2007 976 992
150. L. Troquier, R. Caillierez, S. Burnouf, F.J. Fernandez-Gomez, M.E. Grosjean, N. Zommer, and et al. Targeting phospho-Ser422 by active tau immunotherapy in the THYTau22 mouse model: A suitable therapeutic approach Curr Alzheimer Res 9 2012 397 405
151. C. Theunis, N. Crespo-Biel, V. Gafner, M. Pihlgren, M.P. Lopez-Deber, P. Reis, and et al. Efficacy and safety of a liposome-based vaccine against protein tau, assessed in tau.P301L mice that model tauopathy PLoS One 8 2013 e72301
152. X. Chai, S. Wu, T.K. Murray, R. Kinley, C.V. Cella, H. Sims, and et al. Passive immunization with anti-tau antibodies in two transgenic models: Reduction of tau pathology and delay of disease progression J Biol Chem 286 2011 34457 34467
153. N. Kfoury, B.B. Holmes, H. Jiang, D.M. Holtzman, and M.I. Diamond Trans-cellular propagation of tau aggregation by fibrillar species J Biol Chem 287 2012 19440 19451
154. D.L. Castillo-Carranza, U. Sengupta, M.J. Guerrero-Munoz, C.A. Lasagna-Reeves, J.E. Gerson, G. Singh, and et al. Passive immunization with tau oligomer monoclonal antibody reverses tauopathy phenotypes without affecting hyperphosphorylated neurofibrillary tangles J Neurosci 34 2014 4260 4272
155. Smart Patients. Safety study of AADvac1, a tau peptide-KLH-conjugate active vaccine to treat Alzheimer's disease; 2014. Available at: https://www.smartpatients.com/clinical-trials/NCT01850238. Accessed July 30, 2015.
156. Y. Wang, M. Cella, K. Mallinson, J.D. Ulrich, K.L. Young, M.L. Robinette, and et al. TREM2 lipid sensing sustains the microglial response in an Alzheimer's disease model Cell 160 2015 1061 1071
157. T.R. Jay, C.M. Miller, P.J. Cheng, L.C. Graham, S. Bemiller, M.L. Broihier, and et al. TREM2 deficiency eliminates TREM2+ inflammatory macrophages and ameliorates pathology in Alzheimer's disease mouse models J Exp Med 212 2015 287 295
158. J. Tan, T. Town, F. Crawford, T. Mori, A. DelleDonne, R. Crescentini, and et al. Role of CD40 ligand in amyloidosis in transgenic Alzheimer's mice Nat Neurosci 5 2002 1288 1293
159. J. Tan, T. Town, D. Paris, T. Mori, Z. Suo, F. Crawford, and et al. Microglial activation resulting from CD40-CD40L interaction after beta-amyloid stimulation Science 286 1999 2352 2355
160. J. Tan, T. Town, T. Mori, D. Obregon, Y. Wu, A. DelleDonne, and et al. CD40 is expressed and functional on neuronal cells EMBO J 21 2002 643 652
161. M.E. Gambuzza, V. Sofo, F.M. Salmeri, L. Soraci, S. Marino, and P. Bramanti Toll-like receptors in Alzheimer's disease: A therapeutic perspective CNS Neurol Disord Drug Targets 13 2014 1542 1558
162. J. Kim, A.E. Eltorai, H. Jiang, F. Liao, P.B. Verghese, F.R. Stewart, and et al. Anti-apoE immunotherapy inhibits amyloid accumulation in a transgenic mouse model of Abeta amyloidosis J Exp Med 209 2012 2149 2156
163. M.V. Guillot-Sestier, K.R. Doty, D. Gate, J. Rodriguez Jr., B.P. Leung, K. Rezai-Zadeh, and et al. Il10 deficiency rebalances innate immunity to mitigate Alzheimer-like pathology Neuron 85 2015 534 548
164. P. Chakrabarty, A. Li, C. Ceballos-Diaz, J.A. Eddy, C.C. Funk, B. Moore, and et al. IL-10 alters immunoproteostasis in APP mice, increasing plaque burden and worsening cognitive behavior Neuron 85 2015 519 533
165. T. Town, Y. Laouar, C. Pittenger, T. Mori, C.A. Szekely, J. Tan, and et al. Blocking TGF-beta-Smad2/3 innate immune signaling mitigates Alzheimer-like pathology Nat Med 14 2008 681 687
166. E. Masliah, E. Rockenstein, A. Adame, M. Alford, L. Crews, M. Hashimoto, and et al. Effects of alpha-synuclein immunization in a mouse model of Parkinson's disease Neuron 46 2005 857 868